Clinical Overview
Buprenorphine is a partial opioid agonist indicated for opioid use disorder treatment and chronic pain management. As a partial agonist, it provides sufficient opioid receptor activation to prevent withdrawal while having a “ceiling effect” that reduces overdose risk compared to full opioid agonists.
Primary Clinical Applications
Buprenorphine is indicated for opioid use disorder (OUD) treatment as maintenance therapy and for medically supervised withdrawal. It is available as monotherapy (Subutex) for induction or in combination with naloxone (Suboxone) to deter intravenous abuse. Sublocade is a monthly injection for maintenance therapy.
Mechanism and Clinical Benefits
Buprenorphine’s partial agonist activity at mu-opioid receptors provides sufficient receptor occupancy to prevent withdrawal and craving while having a ceiling effect for respiratory depression. This profile makes it safer than methadone and allows for office-based treatment of OUD.
Treatment Considerations
Buprenorphine requires special DEA certification (DATA waiver) for prescribing for OUD. Treatment involves induction (starting therapy), stabilization, and maintenance phases. The medication can precipitate withdrawal if given too soon after full opioid agonists, requiring careful timing of initiation.
Prescribing Information
Dosing & Administration
Opioid Use Disorder – Induction:
- Day 1: 2-4 mg sublingual (monotherapy preferred for induction)
- Day 2: 4-8 mg sublingual based on withdrawal symptoms
- Timing: Start when moderate withdrawal symptoms present
Maintenance Therapy:
- Target dose: 12-16 mg daily (most patients)
- Range: 4-24 mg daily
- Suboxone: Same dosing as monotherapy once stabilized
Sublocade (Monthly Injection):
- Month 1-2: 300 mg subcutaneous monthly
- Month 3+: 100 mg or 300 mg monthly based on clinical response
- Prerequisite: Stabilized on 8-24 mg daily sublingual buprenorphine
Administration:
- Sublingual: Place under tongue until dissolved, do not swallow
- Timing: Avoid eating/drinking 15 minutes before and after
Indications
- Treatment of opioid use disorder (maintenance therapy)
- Medically supervised withdrawal from opioids
- Off-label: Chronic pain (separate formulations available)
Contraindications
- Hypersensitivity to buprenorphine or naloxone
- Significant respiratory depression
- Acute or severe bronchial asthma
- Paralytic ileus
Warnings & Precautions
- Respiratory depression: Risk increased with CNS depressants, alcohol
- Precipitated withdrawal: Can occur if given too soon after full opioid agonists
- Hepatotoxicity: Monitor liver function, especially in hepatitis patients
- QT prolongation: Monitor in patients with cardiac risk factors
- Dependence: Physical dependence will develop
- Diversion potential: Combination with naloxone reduces abuse potential
Drug Interactions
- CNS depressants: Increased risk of respiratory depression
- CYP3A4 inhibitors: May increase buprenorphine levels
- CYP3A4 inducers: May decrease buprenorphine effectiveness
- Benzodiazepines: Significant respiratory depression risk
Adverse Reactions
Common (≥5%):
- Nausea, headache, vomiting, hyperhidrosis
- Constipation, signs and symptoms of withdrawal
- Insomnia, pain, peripheral edema
Serious:
- Respiratory depression, hepatotoxicity, precipitated withdrawal
Special Populations
- Hepatic Impairment: Use caution, consider dose reduction
- Pregnancy: Category C – benefits may outweigh risks for OUD treatment
- Prescriber Requirements: Requires DATA waiver certification for OUD treatment
- REMS Program: Educational requirements for prescribers
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
